Adding Taxane to Anthracycline-Based Therapy Does Not Improve Outcomes SAN ANTONIO-Giving a taxane following standard anthracycline-based chemotherapy for early breast cancer will not improve outcomes, suggest results of a 104-center, British study presented at the San Antonio Breast Cancer Symposium.There...
TopAbstracts in Breast Cancer 07/01/2008 TopAbstracts in Breast Cancer are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 7 days.Over 2000 peer-reviewed...
Breast Cancer - Research from M. Campone and co-researchers provides new data on breast cancer Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly We're a pay-per-view site for premium content.If you'd like to purchase this article, it's only $3.00.
Breast Cancer Research from M.
Campone and co...
Data Published in Anticancer Research Show ChemoFx(R) Assay Results Correlate With Outcomes in Breast Cancer PITTSBURGH, July 1 /PRNewswire/ -- Precision Therapeutics Inc.announced today that results from the ChemoFx(R) Assay, a cell-based test that examines the response of a specific patient's tumor to various chemotherapies, correlate with...
Data Published in Anticancer Research Show ChemoFx(R) Assay Results Correlate With Outcomes in Breast Cancer PITTSBURGH, July 1 /PRNewswire/ -- Precision Therapeutics Inc.announced today that results from the ChemoFx(R) Assay, a cell-based test that examines the response of a specific patient's tumor to various chemotherapies, correlate with...
Research conducted at University of Auckland has provided new information about cancer - (NewsRx.com) -- According to recent research from Auckland, New Zealand, 'Bovine lactoferrin (bLf), an iron-containing natural defence protein found in bodily secretions, has been reported to inhibit carcinogenesis and the growth of...
Fluorourcil, epirubicin, and cyclophosphamide (FEC) for breast cancer _ Fluorourcil, epirubicin, and cyclophosphamide (FEC) for breast cancer.
Standard therapy plus paclitaxel improves early breast cancer survival Reporter initials SHEETAL Reporter surname LADVA Reporter affiliation Hospital Pharmacist Source J Natl Cancer Inst 2008;100:805-814.Abstract According to results published in the Journal of the National Cancer Institute , adding...
TopAbstracts in Breast Cancer 06/03/2008 TopAbstracts in Breast Cancer are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 7 days.Over 2000 peer-reviewed...
Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Journal of the National Cancer Institute Advance Access originally published online on May 27, 2008 2008 100(11):805-814; doi:10.1093/jnci/djn151 This Article Full Text All Versions of this Article: 100/11/805 most recent djn151v1 Services...
Standard therapy plus paclitaxel improves early breast cancer survival NEW YORK (Reuters Health) - For women with early-stage breast cancer, adding paclitaxel to standard chemotherapy of fluorouracil, epirubicin, and cyclophosphamide (FEC) can improve disease-free survival, Spanish researchers report.
Mutation Spells Bad News for Breast Cancer Patients A mutation in the NQO1 enzyme makes breast cancer cells harder to treat and more likely to spread.Credit: NCI ScienceNOW Daily News Breast cancer patients with a mutation in both copies of the NQO1 gene have a 20% lower survival rate 5...
Standard therapy plus paclitaxel improves early breast cancer survival NEW YORK (Reuters Health) - For women with early-stage breast cancer, adding paclitaxel to standard chemotherapy of fluorouracil, epirubicin, and cyclophosphamide (FEC) can improve disease-free survival, Spanish researchers report.
Paclitaxel improves early breast cancer survival NEW YORK (Reuters Health) - For women with early-stage breast cancer, adding paclitaxel to standard chemotherapy can improve their chances of survival, Spanish researchers report.Miguel Martin, from Hospital Universitario San Carlos in...
First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab in Early Breast Cancer Collaborative groups set out to confirm potential benefits of anticancer therapies to treat women with breast cancer PARIS, May 27, 2008 /PRNewswire/ -- A new international study for women with HER2-positive breast cancer is open for...
Paclitaxel Plus Chemo Improves Outcomes in Early Breast Cancer TUESDAY, May 27 (HealthDay News) -- Adding paclitaxel to standard chemotherapy improved disease-free survival in women with early-stage breast cancer, a Spanish study finds.The phase III trial included 1,246 women with early, non...
Drug-eluting stent having collagen drug carrier chemically treated with genipin Title: United States Patent: 7,351,421 Inventors: Sung; Hsing-Wen (Hsinchu, TW), Chen; Mei-Chin (Taishan Shiang, TW), Tu; Peter Y (Irvine, CA), Tu; Hosheng (Newport Beach, CA) Appl.No.: 10/811,413 Filed: March 26, 2004 A method for...
